Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Leuk Res. 2010 Jan 31;34(10):1351–1357. doi: 10.1016/j.leukres.2009.12.013

Table 2. Comparison of number of CLL patient samples exhibiting upregulation of costimulatory molecules following infection with MVA-TRICOM or MVA-CD40L.

CD40L B7-1 ICAM-1 LFA-3
MVA-TRICOM+ 5/12 12/12 12/12 11/12
MVA-CD40L+ 12/12 10/12 8/12 4/12
MVA-TRICOM+/MVA-CD40L+ 5/12 10/12 8/12 4/12
MVA-TRICOM+/MVA-CD40L- 0/12 2/12 4/12 7/12
MVA-TRICOM-/MVA-CD40L+ 7/12 0/12 0/12 0/12
MVA-TRICOM-/MVA-CD40L- 0/12 0/12 0/12 1/12

CLL cells were infected with either MVA-TRICOM or MVA-CD40L. Flow cytometry analysis was performed 24 hours following infection to determine expression of CD40L and TRICOM molecules by the CLL cells. The number of patient samples exhibiting upregulation of each costimulatory molecule following infection with MVA-TRICOM (MVA-TRICOM+) or MVA-CD40L (MVA-CD40L+) is shown. Samples which did not exhibit upregulation of each costimulatory molecule following infection with MVA-TRICOM or MVA-CD40L are indicated by MVA-TRICOM- and MVA-CD40L-, respectively. The criteria for determining upregulation are explained in “Materials and methods.”